Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery
- PMID: 7995185
- DOI: 10.1007/BF02087696
Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery
Abstract
In an attempt to obtain site-specific delivery of 5-ASA in the intestinal tract, we have determined the extent of absorption and metabolism of a number of novel 5-ASA derivatives, namely, (N-L-glutamyl)-amino-2-salicylic acid (1), (N-L-aspartyl)-amino-2-salicylic-acid (2), 5-aminosalicyl-L-proline-L-leucine (3), and 5-(N-L-glutamyl)-aminosalicyl-L-proline-L-leucine (4), which are selectively cleaved by intestinal brush border aminopeptidase A and carboxypeptidases. These novel prodrugs, 5-ASA, and sulfasalazine were administered to adult Fisher rats (N = 30) and to animals that had undergone prior colostomy (N = 30). Urine and feces were collected at timed intervals for 48 hr and the metabolites, 5-ASA, and N-acetyl-5-ASA were measured by high-performance liquid chromatography. The absorption and metabolism of all compounds were essentially identical in colostomized and normal animals. 5-ASA exhibited a rapid proximal intestinal absorption as evidenced by the high cumulative urinary excretion (> 65%) and low fecal excretion. Sulfasalazine, as expected, exhibited a lower urinary recovery (< 35%) and higher fecal excretion of 5-ASA and its metabolite. The novel glutamate and aspartate derivatives (1 and 2) behaved similarly to sulfasalazine, while administration of the proline-leucine derivative (3) resulted in urinary and fecal recovery values intermediate with respect to those observed with 5-ASA and sulfasalazine. 5-(N-L-Glutamyl)-aminosalicyl-L-proline-L-leucine yielded the highest fecal recovery of 5-ASA and its N-acetyl derivative, indicating a more efficient delivery to the distal bowel. Amino acid derivatives of 5-ASA appear to be potentially useful prodrugs for the site-specific delivery of 5-ASA to different regions of the intestinal tract.
Similar articles
-
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.J Med Chem. 1993 Dec 24;36(26):4201-7. doi: 10.1021/jm00078a009. J Med Chem. 1993. PMID: 8277502
-
Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.Eur J Pharm Sci. 2006 May;28(1-2):26-33. doi: 10.1016/j.ejps.2005.12.005. Epub 2006 Feb 7. Eur J Pharm Sci. 2006. PMID: 16455235
-
5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.Aliment Pharmacol Ther. 1996 Dec;10(6):941-7. doi: 10.1046/j.1365-2036.1996.85257000.x. Aliment Pharmacol Ther. 1996. PMID: 8971292 Clinical Trial.
-
Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.J Pediatr Gastroenterol Nutr. 1989 Apr;8(3):333-8. doi: 10.1097/00005176-198904000-00012. J Pediatr Gastroenterol Nutr. 1989. PMID: 2565380 Review.
-
[New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].Orv Hetil. 1991 Jun 16;132(24):1317-21. Orv Hetil. 1991. PMID: 1677465 Review. Hungarian.
Cited by
-
In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406. doi: 10.1007/BF02353640. J Pharmacokinet Biopharm. 1995. PMID: 8882747